These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19940949)

  • 1. Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients.
    MacArthur RD
    AIDS Rev; 2009; 11(4):223-30. PubMed ID: 19940949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
    Winters B; Van Craenenbroeck E; Van der Borght K; Lecocq P; Villacian J; Bacheler L
    J Virol Methods; 2009 Dec; 162(1-2):101-8. PubMed ID: 19654022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of resistance testing in the management of HIV-1-infected patients.
    Grant PM; Zolopa AR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):474-80. PubMed ID: 20048713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV resistance testing: methods, utility, and limitations.
    Alcorn TM; Faruki H
    Mol Diagn; 2000 Sep; 5(3):159-68. PubMed ID: 11070150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
    Call SA; Saag MS; Westfall AO; Raper JL; Pham SV; Tolson JM; Hellmann NS; Cloud GA; Johnson VA
    J Infect Dis; 2001 Feb; 183(3):401-8. PubMed ID: 11133371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.
    Johnson JA; Geretti AM
    J Antimicrob Chemother; 2010 Jul; 65(7):1322-6. PubMed ID: 20466851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for HIV-1 drug resistance.
    Hanna GJ; Caliendo AM
    Mol Diagn; 2001 Dec; 6(4):253-63. PubMed ID: 11774191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
    Aceti A; Carosi G
    Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into HIV resistance testing: nursing guidelines and implications.
    Kirton CA; Kurtyka D; Sterken DJ
    J Assoc Nurses AIDS Care; 2007; 18(3):74-86. PubMed ID: 17570302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.